<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Multidisciplinary Clinic

Patient Care    Multidisciplinary Clinic    Neuroendocrine

CU Cancer Center Neuroendocrine Tumor Multidisciplinary Clinic

If you drew a line straight back between your eyes, you would hit the pituitary gland in about three inches. Though only about the size of a pea, the pituitary is a master regulator of hormone systems throughout the body. It’s also a fairly common origin of tumors. One in every 10,000 people will be diagnosed with a neuroendocrine tumor originating in the pituitary; one in five people will develop a pituitary mass without knowing it. Most of these pituitary masses aren’t cancer – they become dangerous only when they affect pituitary function or grow large enough to squeeze against other nearby structures, often creating headaches or affecting vision. But some pituitary masses are cancer. Knowing the difference can be tricky and treating these diverse pituitary tumors can be especially challenging.


Author Cancer Center | Publish Date June 24, 2019
Full Story

CU Cancer Center In the News

Targeted Oncology

Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma

news outletTargeted Oncology
Publish DateNovember 16, 2022

During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.

Full Story
Cancer Health

Pancreatic Cancer Survivor Shares a Message of Hope

news outletCancer Health
Publish DateNovember 15, 2022

November is Pancreatic Cancer Awareness Month. Laura Foote shares her story to bring hope and express gratitude.

Full Story
TIME

How Bladder Cancer Differs in Women and Younger Adults

news outletTIME
Publish DateNovember 15, 2022

Men are three to four times more likely than women to develop bladder cancer, but the disease tends to be deadlier in females. Why?

Full Story
Biospace

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

news outletBiospace
Publish DateNovember 14, 2022

New therapeutic addresses need in patients suffering with cold and refractory tumors.

Full Story